Table 3 Clinical characteristics and outcomes of women undergoing cytoreductive surgery and HIPEC
Author | Number of patients | Age (years, mean) | Time since initial treatment (months) | PCI | CRS caracreristics | Morbidity | Mortality | PFS (months, median; range) | OS (months, median) |
|---|---|---|---|---|---|---|---|---|---|
Helm [17] | 5 | 61 | 47 (mean; range 29–66) | – | CCO: 60.0% CC1: 20.0% CC2: 20.0% | Grade 3: 0% Grade 4: 60.0% | 0/5 | 7 (0–32) | 28 |
Bakrin [4] | 5 | 59.6 | 47.5 (mean; range 10–120) | 7 (median; range 5–18) | CC0: 100% | Grade 3: 40.0% Grade 4: 32.0% | 0/5 | 10 (2–39) | 16 |
Santeufemia [16] | 1 | 70 | 120 | – | – | 0% | 0/1 | 12 | 12 |
Delotte [15] | 13 | 66.5 | 18.5 (median; range 0–53) | 12 (median; range 3–24) | CCO: 61.5% CC1: 23.1% CC2: 15.4% | – | 0/13 | 11 (2–124) | 19.4 |
Abu-Zaid [14] | 6 | 55.5 | 9 (mean; range 1–18) | 19 (mean; range 9–26) | CC0: 83.3% CC1: 16.7% | Grade 3: 0% Grade 4: 33.3% | 0/6 | 13 (3–35) | – |
Cornali [13] | 33 | 57.7 | 17.5 (median; range 6–36) | 15 (median; range 5–35) | CCO: 66.7% CC1: 21.2% CC2: 12.1% | Grade 3: 15.2% Grade 4: 3.0% | 1/33 | 18 | 33.1 |
Navarro-Barrios [30] | 43 | 62.0 | – | 12 (median, range 7–19) | CCO: 95% CC1 or 2: 5% | Grade 3: 0% Grade 4: 2% | 0/41 | 5-year: 23% | 5-year: 34% |
CRS + HIPEC group | 30 | 63.9 | 6.8 (median, range 5.1–9.2) | 9 (median; range 5–15) | CCO: 79.3% CC1 or 2: 20.7% | Grade 3 and 4: 20.7% | 0/30 | 10.7 | 19.3 |
CRS only group | 30 | 64.2 | 2.1 (median, range 1.0–5.4) | 10 (mean; range 6–16) | CCO: 74.4% CC1 or 2: 25.6% | Grade 3 and 4: 20.7% | 0/30 | 13.1 | 29.7 |